Quantcast
Last updated on April 25, 2014 at 5:50 EDT

Latest TGen Drug Development Stories

2014-04-24 08:34:02

Will oversee Virginia G. Piper Cancer Center's internationally recognized Phase I clinical trials program SCOTTSDALE, Ariz., April 24, 2014 /PRNewswire-USNewswire/ -- Michael S. Gordon, MD, one of the greater Phoenix area's leading medical oncologists and cancer researchers, has been named the new Medical Director for the Virginia G. Piper Cancer Center Clinical Trials program at Scottsdale Healthcare. Dr. Gordon will oversee the center's internationally recognized Phase I clinical...

2014-04-04 23:33:41

MPI’s Drug Response Predictor (DRP) can generate new and unique clinically relevant gene signatures - a strong complementary drug development tool; TD2 is an oncology drug development company that customizes clinical trial design and execution for its customers by applying rigorous and high-throughput translational preclinical development, with best in class regulatory and clinical expertise. Scottsdale, Ariz., USA and Hoersholm, Denmark (PRWEB) April 03, 2014 Medical Prognosis...

2014-01-14 23:22:43

The Tableau TD2, a popular forensic disk imaging system was compared to CyanLine’s Fast Disk Acquisition System (FDAS) to see which system was faster and more cost-effective; FDAS captures information 6-times faster Eatontown, NJ (PRWEB) January 14, 2014 Capturing both forensic disk images and market share, the popular Tableau TD2 competed against computer forensic company CyanLine’s Fast Disk Acquisition System (FDAS) to determine which system is faster, easier and more economical,...

2013-12-26 23:03:02

Leading forensic imaging systems Tableau TD2 and CyanLine Fast Disk Acquisition System (FDAS) competed side by side to see which system is the fastest and most cost-effective – Results prove FDAS to be 6 times faster. Eatontown, NJ (PRWEB) December 26, 2013 The long-standing king of forensic disk imaging, the Tableau TD2, may no longer reign supreme, as seen in a recent demonstration comparing it to CyanLine’s Fast Disk Acquisition System (FDAS) in speed, ease of use and price. Josh...

2013-09-06 20:20:58

Abraxane now part of standard-of-care for patients with advanced pancreatic cancer, following studies at the Virginia G. Piper Cancer Center at Scottsdale Healthcare SCOTTSDALE, Ariz., Sept. 6, 2013 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Abraxane for patients with advanced pancreatic cancer, following 7 years of rigorous clinical trials overseen by Scottsdale Healthcare and the Translational Genomics Research Institute (TGen). (Logo:...

2013-07-18 11:40:15

Patients benefit from treatments tailored specifically for their tumor types; stage set for larger study The Side-Out Foundation's breast cancer pilot study, led by the Translational Genomics Research Institute (TGen), Translational Drug Development (TD2) and Scottsdale Healthcare, has shown that cancer patients do better when their treatment is guided by molecular profiling. Specifically, 52 percent of patients with advanced breast cancer received clinical benefit -- meaning their...

2013-07-10 12:28:06

"Oncology Protocol Challenge" and New Appointments Underscore Commitment to Cancer Studies ROCKVILLE, Md., July 10, 2013 /PRNewswire-USNewswire/ -- This spring has seen Accelovance, a Rockville, Md. Clinical Research Organization (CRO) serving biotech and small and mid-sized pharmaceutical companies, advance its goal of providing premier services within oncology clinical research. The company successfully completed its first-ever "Oncology Protocol Challenge" at the American...

2013-06-25 04:21:23

Two of Arizona's premier biomedical institutions unite to develop critically needed diagnostic biomarkers for cancer TUCSON, Ariz., June 25, 2013 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, and the Translational Genomics Research Institute (TGen) today announced a collaborative research agreement to discover and develop diagnostic markers for treating cancer. The two Arizona-based institutions will leverage each other's expertise in discovery...

2013-06-21 23:21:42

The new TRC-TD2 partnership will allow investigators the ability to test the efficacy of new radiation techniques with potential new drugs. SCOTTSDALE, Ariz. (PRWEB) June 21, 2013 Cancer pharmaceutical development company, Translational Drug Development (TD2), and the Translational Research Consortium (TRC) today announced a new partnership to enable rapid testing of anti-cancer drugs combined with radiation therapy. The new TRC-TD2 partnership will allow investigators the ability to test...

2013-06-02 23:17:39

The Pancreas Cancer Research Team (PCRT) is the world´s only program dedicated to rapidly translating research discoveries into new treatments and supportive care for patients with pancreas cancer. SCOTTSDALE, Ariz. (PRWEB) June 01, 2013 Ten years after its founding, the Pancreatic Cancer Research Team (PCRT) is announcing the positive results of a large Phase III clinical trial involving more than 800 patients. PCRT is celebrating its 10th anniversary of accelerating new and effective...